Advances in the treatment of soft tissue sarcoma: focus on eribulin

References

• JoVYFletcherCDWHO classification of tumours of soft tissue an update based on the 2013 (4th) editionPathology20144629510424378391
   PubMed Web of Science ®Google Scholar
• ColomboCRandallRLAndtbackaRHIGronchiASurgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneumExpert Rev Anticancer Ther20121281079108723030226
   PubMed Web of Science ®Google Scholar
• CragoAMBrennanMFPrinciples in management of soft tissue sarcomaAdv Surg20154910712226299493
   PubMedGoogle Scholar
• LoizosNXuYHuberJTargeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic targetMol Cancer Ther20054336937915767546
   PubMed Web of Science ®Google Scholar
• TapWDJonesRLVan TineBAOlaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialLancet20163881004348849727291997
   PubMed Web of Science ®Google Scholar
• KaravasilisVSeddonBMAshleySAl-MuderisOFisherCJudsonISignificant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patientsCancer200811271585159118278813
   PubMed Web of Science ®Google Scholar
• LeahyMGarcia Del MuroXReichardtPChemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) studyAnn Oncol Off J Eur Soc Med Oncol2012231027632770
   PubMed Web of Science ®Google Scholar
• MinchomAJonesRFisherCClinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcomaSarcoma2010201026436020508840
   PubMedGoogle Scholar
• RatanRPatelSRChemotherapy for soft tissue sarcomaCancer2016122192952296027434055
   PubMed Web of Science ®Google Scholar
• VlenterieMLitiereSRizzoEOutcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entityEur J Cancer201658627226968015
   PubMed Web of Science ®Google Scholar
• YasuiHNakaNImuraYTailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001Cancer Lett2014347111412224491407
   PubMed Web of Science ®Google Scholar
• CasaliPGAdjuvant chemotherapy for soft tissue sarcomaAm Soc Clin Oncol Educ B2015e629e633
   PubMedGoogle Scholar
• National Center for Biotechnology InformationPubchem Open Chemistry Database –Compound Summary for CID 11354606 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11354606Accessed: August 30, 2017
   Google Scholar
• National Center for Biotechnology InformationPubchem Open Chemistry Database –Compound Summary for CID 5488895 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5488895Accessed: August 30, 2017
   Google Scholar
• McbrideAButlerSKEribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancerAm J Heal Pharm2012699745755
   PubMed Web of Science ®Google Scholar
• TwelvesCCortesJVahdatLTWandersJAkereleCKaufmanPAPhase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic brcast CancerClin Breast Cancer201010216016320299316
   PubMed Web of Science ®Google Scholar
• SchöffskiPChawlaSMakiRGEribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialLancet20163871629163726874885
   PubMed Web of Science ®Google Scholar
• HirataYUemuraDHalichondrins – antitumor polyether macrolides from a marine spongePure Appl Chem1986585701710
   Web of Science ®Google Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMol Cancer Ther2005471086109516020666
   PubMed Web of Science ®Google Scholar
• DabydeenDABurnettJCBaiRComparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulinMol Pharmacol20067061866187516940412
   PubMed Web of Science ®Google Scholar
• WertzIEKusamSLamCSensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Nature2011471733611011421368834
   PubMed Web of Science ®Google Scholar
• EichhornJMSakurikarNAlfordSEChuRChambersTCCritical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic deathCell Death Dis2013410e83424091677
   PubMedGoogle Scholar
• TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res20016131013102111221827
   PubMed Web of Science ®Google Scholar
• Dybdal-HargreavesNFRisingerALMooberrySLEribulin mesylate: mechanism of action of a unique microtubule-targeting agentClin Cancer Res201521112445245225838395
   PubMed Web of Science ®Google Scholar
• FunahashiYOkamotoKAdachiYEribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer modelsCancer Sci2014105101334134225060424
   PubMed Web of Science ®Google Scholar
• KawanoSAsanoMAdachiYMatsuiJAntimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcomaAnticancer Res20163641553156127069131
   PubMed Web of Science ®Google Scholar
• CasazzaADi ConzaGWenesMFinisguerraVDeschoemaekerSMazzoneMTumor stroma: a complexity dictated by the hypoxic tumor microenvironmentOncogene201433141743175423604130
   PubMed Web of Science ®Google Scholar
• YoshidaTOzawaYKimuraTEribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesBr J Cancer201411061497150524569463
   PubMed Web of Science ®Google Scholar
• TakanoSKanaiFJazagASmad4 is essential for down-regulation of E-cadherin induced by TGF-β in pancreatic cancer cell line PANC-1J Biochem2007141334535117301079
   PubMed Web of Science ®Google Scholar
• GregoryPABrackenCPSmithEAn autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transitionMol Biol Cell201122101686169821411626
   PubMed Web of Science ®Google Scholar
• HerbstRSKhuriFRMode of action of docetaxel – a basis for combination with novel anticancer agentsCancer Treat Rev200329540741512972359
   PubMed Web of Science ®Google Scholar
• MillerKDSweeneyCJSledgeJRedefining the target: chemotherapeutics as antiangiogenicsJ Clin Oncol20011941195120611181686
   PubMed Web of Science ®Google Scholar
• GrantDSWilliamsTLZahaczewskyMDickerAPComparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (tax-otere)Int J Cancer2003104112112912532428
   PubMed Web of Science ®Google Scholar
• MakiRGGemcitabine and docetaxel in metastatic sarcoma: past, present, and futureOncologist2007128999100617766660
   PubMed Web of Science ®Google Scholar
• BramwellVHCAndersonDCharetteMLDoxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcomaCochrane Database Syst Rev20033CD00329312917960
   PubMedGoogle Scholar
• HwangCOvercoming docetaxel resistance in prostate cancer: a perspective reviewTher Adv Med Oncol20124632934023118808
   PubMed Web of Science ®Google Scholar
• GoelSMitaACMitaMA phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res200915124207421219509177
   PubMed Web of Science ®Google Scholar
• TanARRubinEHWaltonDCPhase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumorsClin Cancer Res200915124213421919509146
   PubMed Web of Science ®Google Scholar
• MukoharaTNagaiSMukaiHNamikiMMinamiHEribulin mesylate in patients with refractory cancers: a Phase I studyInvest New Drugs20123051926193321887501
   PubMed Web of Science ®Google Scholar
• MorganRJSynoldTWLongmateJAPharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium TrialCancer Chemother Pharmacol201576589790726362045
   PubMed Web of Science ®Google Scholar
• VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol200927182954296119349550
   PubMed Web of Science ®Google Scholar
• CiglerTVahdatLTEribulin mesylate for the treatment of breast cancerExpert Opin Pharmacother20101191587159320450446
   PubMed Web of Science ®Google Scholar
• DevrieseLAWitteveenPOMarchettiSPharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairmentCancer Chemother Pharmacol201270682383223010853
   PubMed Web of Science ®Google Scholar
• TanASarantopoulosJLeeLPharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal functionCancer Chemother Pharmacol2015765105126433580
   PubMed Web of Science ®Google Scholar
• MajidOGuptaAReydermanLOlivoMHusseinZPopulation pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanesJ Clin Pharmacol201454101134114324771603
   PubMed Web of Science ®Google Scholar
• SchöffskiPRay-CoquardILCioffiAActivity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesLancet Oncol201112111045105221937277
   PubMed Web of Science ®Google Scholar
• KawaiAArakiNNaitoYPhase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcomaJpn J Clin Oncol2016472137144
   Web of Science ®Google Scholar
• YoungRJWollPJEribulin in soft-tissue sarcomaLancet20163871594159626874886
   PubMed Web of Science ®Google Scholar
• SwamiUShahUGoelSEribulin in cancer treatmentMar Drugs20151385016505826262627
   PubMed Web of Science ®Google Scholar
• KaufmanPAAwadaATwelvesCPhase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol201533659460125605862
   PubMed Web of Science ®Google Scholar
• KimJIlChoiKULeeISExpression of hypoxic markers and their prognostic significance in soft tissue sarcomaOncol Lett2015941699170625789026
   PubMed Web of Science ®Google Scholar
• KitaharaHHiraiMKatoKBou-GhariosGNakamuraHKawashiriSEribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transitionOncol Rep2016631393144
   Google Scholar
• ZucaliPABertuzziAParraHJSCampagnoliEQuagliuoloVSantoroAThe “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomasInvest New Drugs200826217518117898927
   PubMed Web of Science ®Google Scholar
• DemetriGDVon MehrenMJonesRLEfficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trialJ Clin Oncol201634878679326371143
   PubMed Web of Science ®Google Scholar
• van der GraafWTABlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• LheureuxSOzaAMLaurieSAA phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret ConsortiumBr J Cancer2015113111534154026554651
   PubMed Web of Science ®Google Scholar
• RovielloGMilaniMGobbiAA phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancersClin Breast Cancer2016163e57e5926943987
   PubMed Web of Science ®Google Scholar
• OsgoodCLChukMKTheoretMRFDA approval summary: eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimenClin Cancer Res201723216384638928242632
   PubMed Web of Science ®Google Scholar
• SynoldTWMorganRJNewmanEMA phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium TrialProceedings of the ASCO Annual MeetingMay 13–17, 2005Orlando, FL, USA
   Google Scholar